Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2016 - 2025)

Ani Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $22.6 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.06% year-over-year to $22.6 million; the TTM value through Dec 2025 reached $91.4 million, up 34.97%, while the annual FY2025 figure was $91.4 million, 34.97% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $22.6 million at Ani Pharmaceuticals, roughly flat from $22.6 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $23.3 million in Q2 2025 and bottomed at $10.9 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $14.7 million (2023), against an average of $16.2 million.
  • The largest annual shift saw Depreciation & Amortization (CF) decreased 2.55% in 2021 before it surged 58.41% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.7 million in 2021, then rose by 13.8% to $15.6 million in 2022, then dropped by 2.43% to $15.2 million in 2023, then soared by 48.74% to $22.6 million in 2024, then rose by 0.06% to $22.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Depreciation & Amortization (CF) are $22.6 million (Q4 2025), $22.6 million (Q3 2025), and $23.3 million (Q2 2025).